Skip to main content

Drug Interactions between aminophylline and zileuton

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

aminophylline zileuton

Applies to: aminophylline and zileuton

ADJUST DOSE: Coadministration with zileuton may significantly increase the plasma concentrations of theophylline. The proposed mechanism is zileuton inhibition of theophylline metabolism via CYP450 1A2. In 16 healthy adult male volunteers, administration of theophylline 200 mg four times daily in combination with zileuton 800 mg twice daily for 5 days resulted in an approximately 73% increase in mean steady-state theophylline peak serum concentration (Cmax) and 92% increase in systemic exposure (AUC) compared to administration with placebo. In addition, the apparent plasma clearance of theophylline decreased by nearly 50%, the time to peak concentration (Tmax) delayed by 0.5 hours, and the half-life prolonged by 1.5 hours (24%) during coadministration with zileuton. Fourteen subjects reported 44 mild or moderately severe adverse events possibly or probably related to coadministration of zileuton, including three who withdrew from the study prematurely, compared to eight subjects who reported 8 such events during placebo coadministration.

MANAGEMENT: Caution is advised if theophylline is prescribed in combination with zileuton, particularly in the elderly and patients with chronic obstructive pulmonary disease, congestive heart failure or cirrhosis, as these patients generally have lower theophylline clearance rates and may be particularly vulnerable to theophylline toxicity. When zileuton is initiated in patients receiving theophylline, the theophylline dosage should be reduced by approximately one-half and theophylline levels closely monitored. Similarly, when initiating therapy with theophylline in patients receiving zileuton, the maintenance dosage and/or dosing interval of theophylline should be adjusted accordingly and guided by serum theophylline levels. Patients should be advised to notify their physician if they experience signs and symptoms suggestive of theophylline toxicity such as nausea, vomiting, diarrhea, headache, tremor, irritability, insomnia, seizures, palpitation, or arrhythmia.

References (3)
  1. Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM (1995) "Effect of zileuton on theophylline pharmacokinetics." Clin Pharmacokinet, 29(suppl 2, p. 77-83
  2. "Product Information. Zyflo (zileuton)." Abbott Pharmaceutical
  3. Lau R (1997) "Drug interactions with zileuton." Lancet, 349, p. 1479-80

Drug and food interactions

Moderate

aminophylline food

Applies to: aminophylline

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References (7)
  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.